

Form PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

032026-0700

SERIAL NO.

10/036,819

## INFORMATION DISCLOSURE CITATION

APPLICANT

Hayes et al.

FILING DATE

12/21/2001

GROUP ART UNIT

1616

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SCB		5,446,035	August 29, 1995	Neef et al.	514	167	

RECEIVED

APR 17 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

Sabira Qaz

DATE CONSIDERED

7/25/03

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

BEST AVAILABLE COPY

APR 22 2003

Page 1 of 1

Form PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

032026-0700

SERIAL NO.

10/036,819

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Hayes et al.

FILING DATE

12/21/2001

GROUP ART UNIT

1616

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

RECEIVED

APR 25 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Barrat et al. (DN 136:339213, CAPLUS, abstract of J. of Experimental Medicine (2002), 195(5), 603-616).

Penna et al. (DN 132:292680, CAPLUS, abstract of J. of Immunology (2000), 164(5), 2405-2411).

Dam et al. (DN 132:146376, CAPLUS, abstract of J. of Investigative Dermatology (1999), 113(6), 1082-1089).

EXAMINER

SABHA GAZI

DATE CONSIDERED

7/25/03

- \* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

BEST AVAILABLE COPY

Form PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
032026-0700SERIAL NO.  
10/036,819

APPLICANT

Hayes et al.

#6

FILING DATE

12/21/2001

GROUP ART UNIT

1616

## INFORMATION DISCLOSURE CITATION

APR 21 2003

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Bemiss, C. J. *et al.*, "Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system," *Archives of Biochemistry and Biophysics*, **402** (2002), pp. 249-254; published by Elsevier Science (USA).

Bickston, S.J. *et al.*, "Recombinant Interleukin 10 for the Treatment of Active Crohn's Disease: Lessons in Biologic Therapy," *Gastroenterology*, **119** (6) (2000), pp. 1781-1783; published by American Gastroenterological Association (USA).

Cantorna, M. T. *et al.*, "1,25-Dihydroxycholecalciferol Prevents and Ameliorates Symptoms of Experimental Murine Inflammatory Bowel Disease," *J. Nutr.*, **130** (2000), pp. 2648-2652; published by American Society for Nutritional Sciences (USA).

Colombel, J-F. *et al.*, "Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease," *Gut*, **49** (2001) pp. 42-46; published by British Medical Association (United Kingdom).

Cornillie, F. *et al.*, "Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease," *Aliment Pharmacol Ther.*, **15** (2001), pp. 463-473; published by Blackwell Science Ltd.

EXAMINER

Sabiha Qaz

DATE CONSIDERED

7/25/03

- \* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 032026-0700	SERIAL NO. 10/036,819
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		APPLICANT Hayes et al.	
		FILING DATE 12/21/2001	GROUP ART UNIT #6 1616
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Fedorak, R. N. et al., "Recombinant Human Interleukin 10 in the Treatment of Patients with Mild to Moderately Active Crohn's Disease," <i>Gastroenterology</i> , <b>119</b> (2000), pp. 1473-1482; published by American Gastroenterological Association (USA).	
		Fedorak, R. N. et al., "Human Recombinant Interleukin-10 is Safe and Well Tolerated But Does Not Induce Remission in Steroid Dependent Crohn's Disease," <i>Gastroenterology</i> , <b>120</b> (Supp. 1) (2001), p. A-127; published by W. B. Saunders (Philadelphia, USA).	
		Hanauer, S. B. et al., "Evolving Treatment Strategies for Inflammatory Bowel Disease," <i>Annu. Rev. Med.</i> , <b>52</b> (2001), pp. 299-318; published by Annual Reviews.	
		Kam, L. Y. et al., "TNF- $\alpha$ antagonists for the treatment of Crohn's disease," <i>Exp. Opin. Pharmacother.</i> , <b>1</b> (4) (2000), pp. 615-622; published by Ashley Publications Ltd.	
		Puchner, Thomas C. et al., "Successful Desensitization and Therapeutic Use of Infliximab in Adult and Pediatric Crohn's Disease Patients with Prior Anaphylactic Reaction," <i>Inflamm. Bowel Dis.</i> , <b>7</b> (1) (2001), pp. 34-37; published by Crohn's & Colitis Foundation of America, Inc. (USA).	
		Ricart, E. et al., "Infliximab for Crohn's Disease in Clinical Practice at the Mayo Clinic: The First 100 Patients," <i>Am. J. of Gastroenterology</i> , <b>96</b> (3) (2001), pp. 722-729; published by Am. Coll. of Gastroenterology (USA).	
S. 02		Sandborn, W. J. et al., "An Engineered Human Antibody to TNF (CDP571) for Active Crohn's Disease: A Randomized Double-Blind Placebo-Controlled Trial," <i>Gastroenterology</i> , <b>120</b> (2001), pp. 1330-1338; published by American Gastroenterological Association (USA).	
		Sandborn, W. J. et al., "Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial," <i>Gastroenterology</i> , <b>121</b> (5) (2001), pp. 1088-1094; published by American Gastroenterological Association (USA).	
		Sands, B. E. et al., "Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study," <i>Inflamm. Bowel Dis.</i> , <b>7</b> (2) (2001), pp. 83-88; published by Crohn's & Colitis Foundation of America, Inc. (USA).	
		Schreiber, S. et al., "Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn's Disease," <i>Gastroenterology</i> , <b>119</b> (6) (2000), pp. 1461-1472; published by American Gastroenterological Association (USA).	
TECH CENTER 1600/2900	RECEIVED APR 24 2003	Schreiber, S. et al., "Immunoregulatory Role of Interleukin 10 in Patients With Inflammatory Bowel Disease," <i>Gastroenterology</i> , <b>108</b> (5) (1995), pp. 1434-1444; published by American Gastroenterological Association (USA).	
		Stio, M. et al., "Suppressive effect of 1,25-dihydroxyvitamin D <sub>3</sub> and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis," <i>Biochemical Pharmacology</i> , <b>61</b> (2001), pp. 365-371; published by Elsevier Science Inc.	
		Targan, S. R., "Biology of inflammation in Crohn's disease: Mechanisms of action of anti-TNF- $\alpha$ therapy," <i>Can. J. Gastroenterology</i> , <b>14</b> (Suppl. C) (2000), pp. 13C-16C.	

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 032026-0700	SERIAL NO. 10/036,819
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary) APR 21 2003 PATENT & TRADEMARK OFFICE		APPLICANT Hayes et al. <i>KG</i>	
		FILING DATE 12/21/2001	GROUP ART UNIT 1616
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	van Berge Henegouwen, G. P., ["Consensus for infliximab treatment of patients with Crohn's disease"], <i>Ned Tijdschr. Geneesk.</i> , <b>144</b> (38) (2000), pp. 1844-1845 (Netherlands). English Abstract is provided on page 1845 of the reference.		
	van Deventer, S. J. et al., "Multiple Doses of Intravenous Interleukin 10 in Steroid-Refractory Crohn's Disease," <i>Gastroenterology</i> , <b>113</b> (2) (1997), pp. 383-389; published by American Gastroenterological Association (USA).		
	Harries, A.D. et al., "Vitamin D status in Crohn's disease: association with nutrition and disease activity," <i>Gut</i> , <b>26</b> (1985), pp. 1197-1203.		
	Issenman, R. M., "Bone Mineral Metabolism in Pediatric Inflammatory Bowel Disease," <i>Inflamm. Bowel Dis.</i> , <b>5</b> (3) (1999), pp. 192-199; published by Crohn's & Colitis Foundation of America, Inc. (USA).		
	Jahnsen, J. et al., "Vitamin D Status, Parathyroid Hormone and Bone Mineral Density in Patients with Inflammatory Bowel Disease," <i>Scand. J. Gastroenterol.</i> , <b>37</b> (2002), pp. 192-199; published by Taylor & Francis.		
	Kirchgatterer, A. et al., "Examination, Prevention and Treatment of Osteoporosis in Patients with Inflammatory Bowel Disease: Recommendations and Reality," <i>Acta Medica Austriaca</i> , <b>29</b> (2002), pp. 120-123; U.S. Copyright Clearance Center Code Statement: 0303-8173/2002/2904-0120.		
	Lamb, E. J. et al., "Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease," <i>Aliment Pharmacol. Ther.</i> , <b>16</b> (2002), pp. 1895-1902; published by Blackwell Science Ltd.		
<i>SON</i>	Scharla, S. H. et al., "Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis)," <i>Exp. Clin. Endocrinol.</i> , <b>102</b> (1994), pp. 44-49; published by Johann Ambrosius Barth.		
	Schulte, C. et al., "Reduced Bone Mineral Density and Unbalanced Bone Metabolism in Patients with Inflammatory Bowel Disease," <i>Inflamm. Bowel Dis.</i> , <b>4</b> (4) (1998), pp. 268-275; published by Crohn's & Colitis Foundation of America, Inc. (USA).		
	Silvennoinen, J., "Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease," <i>J. Intern. Med.</i> , <b>239</b> (2) (1996), pp. 131-137; published by Blackwell Science Ltd.		
	Sonnenberg, A. et al., "25-Hydroxycholecalciferol Serum Levels in Patients with Crohn's Disease," <i>Acta Hepato-Gastroenterol.</i> , <b>24</b> (1977), pp. 293-295; published by Georg Thieme Verlag Stuttgart (Germany).		
	Vogelsang, H. et al., "Bone Disease in Vitamin D-Deficient Patients with Crohn's Disease," <i>Digestive Diseases and Sciences</i> , <b>34</b> (7) (1989), pp. 1094-1099; published by Plenum Publishing Corporation (USA).		
	Vogelsang, H. et al., "25-Hydroxyvitamin D. absorption in patients with Crohn's disease and with pancreatic insufficiency," <i>Wien Klin Wochenschr.</i> , <b>109</b> (17) (1997), pp. 678-682; published by Springer-Verlag (Austria).		